Market Exclusivity for Drugs with Multiple Orphan Approvals (1983–2017) and Associated Budget Impact in the US

被引：0
|
作者：
William V. Padula
Sonal Parasrampuria
Mariana P. Socal
Rena M. Conti
Gerard F. Anderson
机构：
[1] University of Southern California,Department of Pharmaceutical and Health Economics, School of Pharmacy, USC Schaeffer Center
[2] University of Southern California,Leonard D. Schaeffer Center for Health Policy and Economics
[3] Johns Hopkins Bloomberg School of Public Health,Department of Health Policy and Management
[4] Boston University Questrom School of Business,Institute for Health System Innovation and Policy
来源：
PharmacoEconomics | 2020年 / 38卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1115 / 1121
页数：6
相关论文
共 50 条
  • [31] Budget impact analysis of drugs for ultra-orphan non-oncological diseases in Europe
    Schlander, Michael
    Adarkwah, Charles Christian
    Gandjour, Afschin
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2015, 15 (01) : 171 - 179
  • [32] A Methodological Review of US Budget-Impact Models for New Drugs
    Mauskopf, Josephine
    Earnshaw, Stephanie
    PHARMACOECONOMICS, 2016, 34 (11) : 1111 - 1131
  • [33] A Methodological Review of US Budget-Impact Models for New Drugs
    Josephine Mauskopf
    Stephanie Earnshaw
    PharmacoEconomics, 2016, 34 : 1111 - 1131
  • [34] Novel orphan medicines and abandoned pathways - the US Orphan Drug Act of 1983 and the impact on rare rheumatologic diseases and lysosomal storage disorders
    Markus Ries
    Thomas Lutz
    Anette Lampert
    William Mountford
    Konstantin Mechler
    Georg F Hoffmann
    Molecular and Cellular Pediatrics, 2 (Suppl 1)
  • [35] US Food and Drug Administration Review Time of Supplemental New Indication Approvals of Drugs and Biologics, 2017 to 2019
    Dhodapkar, Meera M.
    Ross, Joseph S.
    Ramachandran, Reshma
    JAMA NETWORK OPEN, 2023, 6 (06)
  • [36] Pricing and reimbursement policy for new orphan drugs in South Korea: focused on patient accessibility and budget impact
    Lee, Jong Hyuk
    Yoo, Seung-Lai
    EXPERT OPINION ON ORPHAN DRUGS, 2022, 10 (01): : 23 - 28
  • [37] Market Exclusivity and Changes in Competition and Prices Associated With the US Food and Drug Administration Unapproved Drug Initiative
    Gunter, Simon J.
    Kesselheim, Aaron S.
    Rome, Benjamin N.
    JAMA INTERNAL MEDICINE, 2021, 181 (08) : 1124 - 1126
  • [38] The Effect of Market-Based Economic Factors on the Adoption of Orphan Drugs Across Multiple Countries
    John T. Matthews
    Lucas Glass
    Therapeutic Innovation & Regulatory Science, 2013, 47 (2) : 226 - 234
  • [39] The Effect of Market-Based Economic Factors on the Adoption of Orphan Drugs Across Multiple Countries
    Matthews, John T.
    Glass, Lucas
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2013, 47 (02) : 226 - 234
  • [40] US Budget Impact Model for Selinexor in Relapsed or Refractory Multiple Myeloma
    Bassali, Jan
    Gould, Ian Gopal
    Kaye, James A.
    Mladsi, Deirdre
    Mehta, Jyotsna
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2020, 12 : 317 - 325
12345